Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 3046

1.

Development of a Practice Standard for Monitoring Adult Patients Receiving Bone-Modifying Agents at a Community Cancer Center.

Nguyen A, Kalis JA, Sutz TR, Jeffers KD.

J Adv Pract Oncol. 2018 Sep-Oct;9(6):601-607. Epub 2018 Sep 1. Review.

2.

Defining consensus opinion to develop randomised controlled trials in rare diseases using Bayesian design: An example of a proposed trial of adalimumab versus pamidronate for children with CNO/CRMO.

Ramanan AV, Hampson LV, Lythgoe H, Jones AP, Hardwick B, Hind H, Jacobs B, Vasileiou D, Wadsworth I, Ambrose N, Davidson J, Ferguson PJ, Herlin T, Kavirayani A, Killeen OG, Compeyrot-Lacassagne S, Laxer RM, Roderick M, Swart JF, Hedrich CM, Beresford MW.

PLoS One. 2019 Jun 5;14(6):e0215739. doi: 10.1371/journal.pone.0215739. eCollection 2019.

3.

Chronic Recurrent Multifocal Osteomyelitis of the Hand: A Rare Pediatric Condition.

Karunaratne YG, Davies J, Carty CP, Graham D.

Hand (N Y). 2019 May 29:1558944719846599. doi: 10.1177/1558944719846599. [Epub ahead of print]

PMID:
31137982
4.

Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody.

von Moos R, Costa L, Gonzalez-Suarez E, Terpos E, Niepel D, Body JJ.

Cancer Treat Rev. 2019 Jun;76:57-67. doi: 10.1016/j.ctrv.2019.05.003. Epub 2019 May 15. Review.

5.

De-escalation of bone-modifying agents in patients with bone metastases from breast cancer: a systematic review and meta-analysis.

Awan AA, Hutton B, Hilton J, Mazzarello S, Van Poznak C, Vandermeer L, Bota B, Stober C, Sienkiewicz M, Fergusson D, Shorr R, Clemons M.

Breast Cancer Res Treat. 2019 May 11. doi: 10.1007/s10549-019-05265-1. [Epub ahead of print] Review.

PMID:
31079283
6.

Cyclic pamidronate treatment for osteogenesis imperfecta: Report from a Brazilian reference center.

Pinheiro B, Zambrano MB, Vanz AP, Brizola E, Souza LT, Félix TM.

Genet Mol Biol. 2019 Apr 25. pii: S1415-47572019005019401. doi: 10.1590/1678-4685-GMB-2018-0097. [Epub ahead of print]

7.

Two cases of spontaneous remission of primary hyperparathyroidism due to auto-infarction: different management and their outcomes.

Novodvorsky P, Hussein Z, Arshad MF, Iqbal A, Fernando M, Munir A, Balasubramanian SP.

Endocrinol Diabetes Metab Case Rep. 2019 May 7;2019. pii: EDM180136. doi: 10.1530/EDM-18-0136. [Epub ahead of print]

8.

Adjuvant bisphosphonates or RANK-ligand inhibitors for patients with breast cancer and bone metastases: A systematic review and network meta-analysis.

Tesfamariam Y, Jakob T, Wöckel A, Adams A, Weigl A, Monsef I, Kuhr K, Skoetz N.

Crit Rev Oncol Hematol. 2019 May;137:1-8. doi: 10.1016/j.critrevonc.2019.02.004. Epub 2019 Feb 19.

9.

The Bone Phenotype and Pain Response to Pamidronate in Tyrosine Kinase Inhibitor-Treated Chronic Myelogenous Leukemia.

Lavoie DCT, Robinson ME, Johnston D, Pagé M, Konji VN, Rauch F, Ward LM.

J Endocr Soc. 2019 Mar 11;3(5):857-864. doi: 10.1210/js.2018-00268. eCollection 2019 May 1.

10.

Response to Early-onset Pamidronate Treatment in Chronic Non-Bacterial Osteomyelitis: A Retrospective Single Center Study.

Andreasen CM, Jurik AG, Glerup M, Høs C, Mahler B, Hauge EM, Herlin T.

J Rheumatol. 2019 Apr 15. pii: jrheum.181254. doi: 10.3899/jrheum.181254. [Epub ahead of print]

PMID:
30988129
11.
12.

Role of Bisphosphonates in Breast Cancer Therapy.

Goldvaser H, Amir E.

Curr Treat Options Oncol. 2019 Mar 14;20(4):26. doi: 10.1007/s11864-019-0623-8. Review.

PMID:
30874905
13.

Ex Vivo Expanded Human Vγ9Vδ2 T-Cells Can Suppress Epithelial Ovarian Cancer Cell Growth.

Mao TL, Miao CH, Liao YJ, Chen YJ, Yeh CY, Liu CL.

Int J Mol Sci. 2019 Mar 6;20(5). pii: E1139. doi: 10.3390/ijms20051139.

14.

Evaluation of Treatment Patterns and Costs in Patients with Prostate Cancer and Bone Metastases.

Wen L, Yao J, Valderrama A.

J Manag Care Spec Pharm. 2019 Mar;25(3-b Suppl):S1-S11. doi: 10.18553/jmcp.2019.25.3-b.s1.

15.

Visual Diagnosis: An Infant with Rash and Hypercalcemia.

Arango ML, Shah AN.

Pediatr Rev. 2019 Mar;40(3):e11-e13. doi: 10.1542/pir.2017-0058. Epub 2019 Mar 1. No abstract available.

PMID:
30824504
16.

Aminobisphosphonate-associated orbital and ocular inflammatory disease.

Keren S, Leibovitch I, Ben Cnaan R, Neudorfer M, Fogel O, Greenman Y, Shulman S, Zur D, Habot-Wilner Z.

Acta Ophthalmol. 2019 Feb 28. doi: 10.1111/aos.14063. [Epub ahead of print]

PMID:
30816018
17.

Efficacy of bisphosphonates in patients with synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome: a prospective open study.

Li C, Zhao Y, Zuo Y, Zhou Y, Zhang F, Liu S, Zhu Q, Chen J, Zhang W, Xu W, Gu Z, Li L, Li F, Tao W, Cao Y, Sun X, Jing H, Chen H, Zhang S, Dong Z, Liu J, Shi X, Hao W, Qiu G, Zhang W, Wu N, Wu Z.

Clin Exp Rheumatol. 2019 Feb 7. [Epub ahead of print]

PMID:
30767869
18.

Sodium thiosulfate and pamidronate for treatment of calciphylaxis: case report.

Fernández Cañabate S, Alvarez CL, Ortega Valin L, Estifan Ksabji J.

Colomb Med (Cali). 2018 Dec 30;49(4):288-291. doi: 10.25100/cm.v49i3.4134.

19.

WNT1-associated osteogenesis imperfecta with atrophic frontal lobes and arachnoid cysts.

Kantaputra PN, Sirirungruangsarn Y, Visrutaratna P, Petcharunpaisan S, Carlson BM, Intachai W, Sudasna J, Kampuansai J, Dejkhamron P.

J Hum Genet. 2019 Apr;64(4):291-296. doi: 10.1038/s10038-019-0565-9. Epub 2019 Jan 28.

PMID:
30692598
20.

Primary isolated hepatosplenic sarcoidosis mimicking malignancy and causing symptomatic hypercalcaemia.

Haykal T, Sundus S, Bachuwa G, Danish R.

BMJ Case Rep. 2019 Jan 22;12(1). pii: e227703. doi: 10.1136/bcr-2018-227703.

PMID:
30674496

Supplemental Content

Loading ...
Support Center